EX-99.1 2 a12432exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
 

Exhibit 99.1
COVER

 

 

Forward-Looking Statement
This presentation contains forward-looking statements that involve risks and uncertainties, including, but not limited to, the company’s ability to obtain approval of pipeline candidates including Zelapar Viramidine, Pradefovir and Retigabine, within the company’s estimated timeline or at all, and successfully expand the company’s neurology business, success of efforts to develop, acquire and market new products, and to refocus marketing of existing products, marketplace acceptance of the company’s products, success of the company’s strategic repositioning initiatives and the ability of management to execute them, cost-cutting measures, and other risks detailed from time-to-time in the company’s Securities and Exchange Commission filings.
VALEANT

 

 

VALEANT
(NYSE:VRX)
A unique, GLOBAL, research-based,
specialty pharmaceutical company
that discovers, develops, manufactures and markets pharmaceutical products
in the areas of neurology, infectious disease and dermatology

 

 

Company Profile
$683 Million in Revenues*
420 Products
2,342 SKUs
1,000 Sales Representatives Research & Development
Global Manufacturing 3,800 Employees

 

 

Strategic Plan
Innovate & Grow
Transform
Restructure

 

 

Restructuring and Transformation
Focused on Specialty Pharmaceuticals
Grew Core Business Faster than Industry
Built New Management Team
Improved Governance Standards
Divested Non-core Assets
Reacquired R&D Capability
Restructured Debt

 

 

Restructuring and Transformation Focused on Specialty Pharmaceuticals
Grew Core Business Faster than Industry
Built New Management Team
Improved Governance Standards
Divested Non-core Assets
Reacquired R&D Capability
Restructured Debt

 

 

 

 

 

 

 

 

Grow Strategy

 

 

Grow Strategy

 

 

Grow Strategy

 

 

Grow Strategy

 

 

Grow Strategy

 

 

Three Therapeutic Areas

 

 

Ten Global Brands

 

 

Promoted Brands

 

 

North America

 

 

Diastat

 

 

EFUDEX

 

 

KINERASE

 

 

CESAMET

 

 

MIGRANAL

 

 

North America Efficiency

 

 

Europe

 

 

TASMAR

 

 

Dermatix

 

 

Mestinon

 

 

EURO EFF

 

 

Latin America

 

 

Beaoyecta

 

 

Latin America Efficiency

 

 

AAA

 

 

Nyal

 

 

Global Pharmaceutical Market

 

 

 

 

 

 

Growth Strategy

 

 

2005 R&D Pipeline

 

 

New

 

 

Zydis Technology

 

 

Parkinson’s Disease Product Comparisons

 

 

Zelapar: Decrease in OFF Time

 

 

Zelapar: Increase in Dyskinesia-Free ON Time

 

 

VIRAMIDINE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pradefovir Update

 

 

Pipeline Projection

 

 

Performance Goals

 

 

 

 

Financial Review

 

 

Product Sales

 

 

Adjusted Operating Income

 

 

OPERATING INCOME

 

 

R & D Investment

 

 

SOLID BAL SHEET

 

 

EBITDA

 

 

Financial Metrics